Oruka Therapeutics Inc (ORKA)

Currency in USD
91.500
-2.810(-2.98%)
Closed·
91.5000.000(0.00%)
·
ORKA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
91.23094.850
52 wk Range
14.665115.515
Key Statistics
Prev. Close
94.31
Open
93.59
Day's Range
91.23-94.85
52 wk Range
14.665-115.515
Volume
499.38K
Average Volume (3m)
1.15M
1-Year Change
470.0935%
Book Value / Share
18.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORKA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
155.000
Upside
+69.40%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings downwards for the upcoming period

Oruka Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 155.000
(+69.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy120.00+31.15%-MaintainSep 03, 2026
UBS
Buy130.00+42.08%100.00MaintainJul 01, 2026
H.C. Wainwright
Buy120.00+31.15%-MaintainJun 23, 2026
H.C. Wainwright
Buy120.00+31.15%-MaintainJun 03, 2026
Piper Sandler
Buy180.00+96.72%-MaintainJun 02, 2026

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-0.55 / -0.51
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ORKA Income Statement

Compare ORKA to Peers and Sector

Metrics to compare
ORKA
Peers
Sector
Relationship
P/E Ratio
−55.2x−2.0x−0.4x
PEG Ratio
−9.990.010.00
Price/Book
5.4x1.4x2.6x
Price / LTM Sales
-160.6x3.0x
Upside (Analyst Target)
69.5%194.1%49.7%
Fair Value Upside
Unlock8.1%6.8%Unlock

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
26.90M40.64%2.49B
Other Institutional Investors
62.25M59.36%5.76B
Public Companies & Retail Investors
0.000.00%0.00
Total
89.16M100.00%8.25B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC13.68%9,057,645837,923
BlackRock, Inc.7.54%4,990,181461,642

People Also Watch

207.68
RVMD
+0.17%
82.65
ARWR
-2.89%
33.67
TENB
-0.09%
15.700
ERAS
-3.56%
241.31
JAZZ
+0.52%

FAQ

What Is the Oruka Therapeutics (ORKA) Stock Price Today?

The Oruka Therapeutics stock price today is 91.500 USD.

What Stock Exchange Does Oruka Therapeutics Trade On?

Oruka Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Oruka Therapeutics?

The stock symbol for Oruka Therapeutics is "ORKA."

What Is the Oruka Therapeutics Market Cap?

As of today, Oruka Therapeutics market cap is 6.060B USD.

What Is Oruka Therapeutics's Earnings Per Share (TTM)?

The Oruka Therapeutics EPS (TTM) is -2.024.

When Is the Next Oruka Therapeutics Earnings Date?

Oruka Therapeutics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is ORKA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Oruka Therapeutics Stock Split?

Oruka Therapeutics has split 6 times.

What is the current trading status of Oruka Therapeutics (ORKA)?

As of Sep 09, 2026, Oruka Therapeutics (ORKA) is trading at a price of 91.500 USD, with a previous close of 94.310 USD. The stock has fluctuated within a day range of 91.230 USD to 94.850 USD, while its 52-week range spans from 14.665 USD to 115.515 USD.

What Is Oruka Therapeutics (ORKA) Price Target According to Analysts?

The average 12-month price target for Oruka Therapeutics is 155.000 USD, with a high estimate of 200 USD and a low estimate of 117 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +69.40% Upside potential.

What Is the ORKA Premarket Price?

ORKA's last pre-market stock price is 93.950 USD. The pre-market share volume is 13,840.000, and the stock has decreased by -0.360, or -0.380%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.